Sign In
Buy OVID
$2.40
-0.0800 (-3.23%)
At Close: Jun 05, 2026
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
08:30am, Wednesday, 23'rd Jul 2025
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant un
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
08:00am, Wednesday, 25'th Jun 2025
Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP cost
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
10:15am, Tuesday, 13'th May 2025
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
08:00am, Tuesday, 13'th May 2025
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid's first program in its KCC2 direct activator library, OV350, ha
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:05am, Tuesday, 06'th May 2025
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
10:10am, Tuesday, 11'th Mar 2025
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago.
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
08:00am, Tuesday, 11'th Mar 2025
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move i
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
08:00am, Monday, 03'rd Mar 2025
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant u
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
08:00am, Thursday, 27'th Feb 2025
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Wednesday, 05'th Feb 2025
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, toda
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
10:31am, Tuesday, 12'th Nov 2024
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
08:00am, Wednesday, 11'th Sep 2024
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditi
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 20'th Aug 2024
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm
11:00am, Monday, 19'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
11:00am, Sunday, 18'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti
